Short Interest in Silence Therapeutics plc (NASDAQ:SLN) Increases By 15.0%

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,300,000 shares, an increase of 15.0% from the January 15th total of 1,130,000 shares. Based on an average daily volume of 565,200 shares, the short-interest ratio is presently 2.3 days.

Silence Therapeutics Stock Up 1.4 %

Shares of NASDAQ:SLN traded up $0.07 during trading on Wednesday, reaching $5.00. 226,809 shares of the company traded hands, compared to its average volume of 352,313. The firm has a fifty day simple moving average of $5.91 and a 200 day simple moving average of $12.42. The firm has a market cap of $144.85 million, a P/E ratio of -3.18 and a beta of 1.05. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SLN shares. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Chardan Capital reiterated a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, February 11th. They set a "sell" rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, Silence Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $45.00.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its stake in shares of Silence Therapeutics by 424.8% in the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after purchasing an additional 849,676 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $11,635,000. Redmile Group LLC lifted its stake in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock valued at $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Silence Therapeutics by 48,165.6% in the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock valued at $3,434,000 after purchasing an additional 498,032 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company's stock valued at $8,505,000 after purchasing an additional 321,300 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.